Screener
Travere Therapeutics, Inc. TVTX Royalty expense
Royalty expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of goods sold | 1,950 | 4,679 |
| Research and development | 57,094 | 46,889 |
| Selling, general and administrative | 80,254 | 60,413 |
| Royalty expense | 24,816 | 12,425 |
| Total operating expenses | 164,114 | 124,406 |
| Operating loss | (36,915) | (42,674) |
| Other income, net: | ||
| Interest income | 2,584 | 3,795 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s royalty expense?
- Travere Therapeutics, Inc. (TVTX) reported royalty expense of $24.82M in Q1 2026.
Ask your AI about Travere Therapeutics, Inc.'s royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude